 Accordingly, novel treatment concepts are urgently needed in pancreatic cancer and pre-clinical data indicate an important role of the EGFR1erbB2 receptor signalling in the pathogenesis of pancreatic adenocarcinoma Yeh 2007 24. A recent publication Larbouret 2010 16 indicates that the combination of cetuximab and trastuzumab induced superior antitumour activity in human pancreatic carcinoma xenografts compared to gemcitabine alone see also Larbouret 2007 15. Furthermore, synergistic antitumour activity was observed when monoclonal antibodies directed against the EGFR1 and erbB2 were combined Ben-Kasus 2009 3. Based on these data, there is a good rationale to further investigate the combined inhibition of the erbB family in pancreatic cancer patients. 